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The interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is
accepted as a determinant factor for a significant proportion of human malignancies. Recent evidence has highlighted the key role
of epigenetic mechanisms in mediating gene–environment interactions and translating exposures into tumorigenesis. There is
also growing evidence that epigenetic changes may be risk factor-specific (“fingerprints”) that should prove instrumental in the
discovery of new biomarkers in cancer. Here, we review the state of the science of epigenetics associated with environmental
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stimuli and cancer risk, highlighting key developments in the field. Critical knowledge gaps and research needs are discussed and
advances in epigenomics that may help in understanding the functional relevance of epigenetic alterations. Key elements required
for causality inferences linking epigenetic changes to exposure and cancer are discussed and how these alterations can be
incorporated in carcinogen evaluation and in understanding mechanisms underlying epigenome deregulation by the environment.
Epidemiological studies have uncovered robust and consistent
associations between environmental factors and cancer risk.
However, these associations provide little information on the
mechanism by which a given exposure leads to cancer. The
interaction between the (epi)genetic makeup of an individual
and his/her environmental exposure record (exposome)1 may
determine a large fraction of human malignancies.
Epigenetic disruption is a near-universal feature of human
malignancy and a key driver of many cancers.2 In recent years,
accumulating evidence has highlighted the key role of epigenetics
in mediating gene–environment interactions and their effect
throughout the tumorigenesis process3 (Fig. 1). This progress
has been catalyzed by advances in the epigenomic ﬁeld, including
the emergence of powerful technologies and state-of-the-art
in vitro and in silico computational approaches. Well-established
risk factors of cancer, such as age, inﬂammation, diet, and smok-
ing have been studied in the context of epigenome deregulation,
along with some less widely studied exposures and lifestyle fac-
tors such as air and water pollution, fungal toxins and endocrine
disruptors (Fig. 1). Notably, numerous international cohorts
have been established enabling an investigation of life course
exposures on epigenetic proﬁles in the context of large-scale epi-
demiological studies.4
Here, critical knowledge gaps and research needs are dis-
cussed and advances in epigenomics that may help an under-
standing of the functional relevance of epigenetic alterations
induced by environmental exposures. All co-authors of this
work have met during the ﬁrst Environmental and Epigenet-
ics Origin of Cancer meeting, held at IARC, Lyon, in June
2016 and have extensively interacted during and after the
meeting to concretize in this article the valuable conclusions,
arguments and highlights in the ﬁeld. Accordingly, this man-
uscript is not intended to be a meeting report as it does not
merely summarize different scientiﬁc opinions nor does it
represent a review of the literature. Instead, it is intended to
bring forward critical questions that need to be answered,
approaches and study designs that could help answering
them, methodology developments that could be implemented,
important ﬁndings attained so far as examples, future
utilities of the ﬁeld and the direction(s) toward which all
these developments could steer the ﬁeld.
Risk Factors Associated With Epigenome
Deregulation and Cancer
The mechanisms by which environmental factors can have long-
lasting effects on cancer outcome remain poorly understood
(Fig. 1). For example, tobacco smoke has well-established effects
on blood DNA methylation of newborns, children and adults,5,6
though it remains unclear how these effects contribute to
tumorigenesis. In addition, nutrition was shown to affect meta-
stable epialleles (MEs), exhibiting systemic (not cell type-spe-
ciﬁc) interindividual variation in DNA methylation7; however,
whether these epigenetic polymorphisms may be useful as a pre-
dictor of cancer risk remains to be tested. Associations between
folate status, methylation and human colon cancer have been
established in the prevention of malignancy,8 but a protective
role for folate against carcinogenesis has recently been ques-
tioned, with increasing evidence that excessive intake of synthetic
folic acid may actually increase the risk of certain human
malignancies.9
Environmental contaminants (such as inorganic arsenic)
were shown to be associated with methylation changes in infant
cord blood,10 suggesting the “transcription factor occupancy the-
ory” as an underlying mechanism.11 Air pollution represents
another epigenome disruptor; a recent meta-analysis showed
that nitrous dioxide exposure during pregnancy is associated
with cord blood differential DNA methylation in mitochondrial-
related genes.12 Endocrine-disrupting chemicals (EDCs) repre-
sent another example of pollutants that may deregulate the
epigenome13 and contribute to the development of speciﬁc
malignancies, especially hormone-deregulated cancers, although
mechanism remains largely undetermined.14
Infection agents and chronic inﬂammation are also known
to affect epigenetic states. For example, the maternal micro-
biome and the postnatal gut microbiome seem to play a role in
modulating intestinal mucosal epigenetic patterning and conse-
quent susceptibility to inﬂammatory bowel disease (IBD) and
young-onset colorectal cancer.15,16 Another example is the epi-
genetic ﬁeld cancerization observed in gastric cancer, where
chronic inﬂammation induced by Helicobacter pylori is respon-
sible for aberrant DNA methylation.17 In addition, oncogenic
viruses such as Hepatitis B virus and Epstein–Barr virus are
known to hijack the host epigenetic machinery to promote its
replication and to cloak itself from the host surveillance system,
but potentially leaving a recognizable epigenetic signature.18
The fact that infection-related cancers are often characterized
by DNA methylation changes extending to noncancer adjacent
tissues suggests that these alterations may be the result of a
complex process involving chronic inﬂammation, immune
response and changes in cell distribution in addition to possible
direct effects of infectious agents or their mediators (e.g., viral
proteins).
Exposure Timing and Epigenome Deregulation
In addition to the type of environmental exposure, timing also
plays an important role in inﬂuencing disease risk. Embryonic
life and fetal life comprise sensitive periods in the human life
cycle due to the capacity for changes in cell fate during
M
in
i
R
ev
ie
w
Herceg et al. 875
Int. J. Cancer: 142, 874–882 (2018) VC 2017 International Agency for Research on Cancer (IARC/WHO); licensed by UICC
embryonic development, with potentially lifelong health out-
comes. Epigenetic mechanisms represent likely “mediators” of
these outcomes because they are implicated in (i) pathways
driving embryogenesis, including tissue differentiation, (ii)
mitotically heritable mechanisms with long lasting effects, and
(iii) environmentally sensitive and potentially reversible molec-
ular drivers of disease. There is increasing evidence showing
how in utero exposure leaves epigenetic marks in the fetus, and
these include food contaminants such as arsenic and heavy
metals,19 aﬂatoxin B120 and tobacco smoke.5 The inﬂuence of
many of these environmental contaminants on childhood can-
cer has yet to be evaluated. These ﬁndings do suggest, however,
that critical time points for intervention and prevention strate-
gies may occur early in life.
In addition to the embryonic period, environmental and
epigenetic inﬂuences may alter other developmental stages,
such as childhood and puberty, especially in females.
In males, spermatogenesis starts at puberty and continues
throughout life; whereas, in females, oogenesis begins before
birth and is arrested in the prophase of meiosis until puberty.
Hence, in girls, oocytes remain until puberty in a haploid
demethylated state, which is more susceptible to environmen-
tal stressors than the diploid methylated state of the male
germline. Later during adulthood, women may exhibit other
susceptible windows of exposure during the menstrual cycle,
pregnancy or menopause. These timing windows of expo-
sures must be considered when analyzing the interaction
between the environment, epigenetics and cancer.
Research Gaps and Needs
Until very recently, there was a major gap in our understanding
of the “normal” epigenome and its normal variability.21 As the
capacity to map the epigenome continues to increase, the catalog
of epigenetic variations associated with adverse environmental
Figure 1. Exposures arising from external sources (environmental chemicals, air pollution, infectious agents, diet, tobacco, alcohol,
endocrine disruptors) and internal processes (metabolism, hormones, inflammation, gut microflora, aging) may induce stable and
potentially reversible changes in the epigenome. The patterns (“signatures”) and persistence of these alterations depend on multiple
factors, including the type of epigenetic changes (some genomic regions remain methylated for longer periods than others), the dosage
and duration of the exposure (longer and more intense exposures could minimize reversibility of DNA methylation), the tissue type and the
developmental stage (in utero life or puberty may be particularly sensitive periods to some exposure). Thus, epigenetic mechanisms may
represent “sensors” of exposure and “mediators” of the outcomes, including cancer development. Epigenome alterations should prove
instrumental in discovery of new biomarkers for risk stratification and early detection and attractive targets for novel therapies and
preventive strategies.
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exposures will undoubtedly expand.22 The speciﬁc research ques-
tions highlighted below warrant particular attention in that they
remain equivocal or have not been fully addressed.
Strengthening causal inference
To better infer causality of epigenetic associations linking
environmental exposure and cancer, several critical scientiﬁc
approaches are needed (Figs. 1 and 2):
(1) Establishing mechanistic causes through the use of cellular
and animal models, which allow the systematic manipulation of
variables (Fig. 2). Based on mouse models, an important ques-
tion of epigenetic cause versus consequence is being addressed
across several windows of mouse development, showing that
developmental reprogramming of H3K4me3 is acutely induced
by EDCs, persists across the life-course, increases responsive-
ness to hormones without being dependent on abnormal
transcription and promotes the development of hormone-
dependent tumors.13
(2) Coupling epigenetic mechanisms to other molecular
players (including cross-omics). For example, epigenetic marks
can be functionally annotated to gene expression data and
can be associated with causality through genetic variant ran-
domization. Epigenetic variants that are causal to cancer
would likely demonstrate functional consequences on gene
activity or cellular function. Optimized statistical approaches
are equally important and this is demonstrated through the
example on the aryl-hydrocarbon receptor repressor (AHRR)
methylation, which is to date the most consistent epigenetic
signature of tobacco smoking. Although cigarette smoke is
the strongest exposure factor causing lung cancer, the role of
AHRR methylation in the causal pathway from smoking to
lung cancer (as estimated by mediation analysis23) would
require further evidence by Mendelian Randomization.24,25
Figure 2. An integrated approach for the production and integration of epigenetic data in carcinogen identification and evaluation. This
approach implies the use of cutting edge epigenomics, population-based cohorts, and innovative bioinformatics tools for the identification,
quantification, mapping of changes in the epigenome induced by known and suspected carcinogens. Human tumor samples from case–
control and population-based cohorts are used in combination with in vitro cell systems and mouse models to perform epigenomic profiling
to identify signatures, genes and pathways that are deregulated by specific risk exposure. This is followed by validation in population-
based cohorts and where appropriate the data are crossed with the epigenomic databases. Identification of genes and pathways is fol-
lowed by functional studies to provide biological plausibility to associations that are observed. The outcome is providing evidence base for
studies directly relevant to cancer causation and prevention and identification of markers for early detection and cancer risk stratification.
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(3) Integrating epigenetics within well-designed epidemiologi-
cal studies, particularly prospective cohort designs (Fig. 1). Cohort
studies enable the identiﬁcation of “driver” epigenetic alterations
that occur prior to disease onset, and hence, avoid confounding
by “passenger” events that are induced by the disease (reverse
causality). Moreover, longitudinal cohorts that start in early life
can contribute to our understanding of how the epigenome
changes over critical periods throughout life, while cohort studies
based on twin pairs can help disentangle the causal contribution
of genetics relative to epigenetics in mediating the response to
environmental cues and risk to cancer (Fig. 1). Evidence from
the Peri/Postnatal Epigenetic Twins Study showed the role of
both environment and genetic variation in determining neonatal
epigenetic proﬁle, with the heritability of DNA methylation pro-
ﬁles estimated at 15–20%.26 The environmental exposures per se
also should be better estimated, especially given that long-term
exposures cannot be measured with the same degree of accuracy
as in short-term experimental studies. Another criterion in well-
designed studies is their ability to reproduce observed associa-
tions in multiple cohorts and large sample sizes. The Pregnancy
and Childhood Epigenetics Consortium (PACE) and Cohorts
for Heart and Aging Research in Genomic Epidemiology
(CHARGE) consortia provide interesting examples of the largest
studies to date analyzing the effects of environmental exposure
on epigenetic alterations in birth and adult cohorts, respectively.
(1) Epigenetic mechanisms in relevance to biochemical
precursors of DNA methylation. Although folate, a methyl
donor, has a strong impact on DNA methylation and cancer,
the directionality of those effects remains questionable. For
example, high folate levels may lead to both high and low
DNA methylation and to both increased and decreased risk
of cancer. These seemingly contradicting ﬁndings become
more biologically plausible upon dissecting the effect of folate
exposure by dosage, timing, target genes and cancer types.
Mouse studies directly testing the effect of folic acid intake at
various stages of the life course and on various tissues may
be particularly important for ﬁne tuning the intricate associa-
tions between folate exposure, epigenetics and cancer. Addi-
tionally, the inﬂuence of folate species on methylation and
cancer risk remains to be established.
(2) Epigenetic mechanisms in relevance to transcriptional
machinery. Although DNA hypermethylation in the promoters
of many genes is generally associated with transcriptional
silencing, the importance of the link between epigenetics and
transcription remains an open question. CpG methylation that
is not associated with RNA expression may have little func-
tional relevance, but this is questioned by the evidence showing
how developmental reprogramming involving the remodeling
of chromatin marks may lead to increased responsiveness to
hormones without necessarily altered transcription.13 It also
remains to be established to what extent the link between
methylation and expression is due to loss of transcription factor
binding.27 Moreover, much remains to be learned about the
functional regulation of ultralow methylation regions
(ULMRs), which are methylated at 1–20% and rarely studied
using traditional methodologies (J.P. Issa, unpublished data).
(3) Epigenetic mechanisms in relevance to chromatin land-
scape. While DNA methylation is known to be transmitted with
high ﬁdelity across cell divisions, the chromatin landscape is less
characterized, and it is still unclear how a deﬁned chromatin
domain is reproduced following cell replication. Recently, the
Polycomb Repressive Complex 2 has been implicated in the
inheritance of histone modiﬁcations across cell divisions.28 How-
ever, none of the existing techniques for analysis of histone mod-
iﬁcations is ready to use on the biospecimen types and sample
size scales that are utilized in population-based studies. The
advent of new technologies in chromatin biology holds promise
for future studies aiming to investigate the role of chromatin in
mediating effects of environmental exposures on cancer.
(4) Epigenetic mechanisms in relevance to epidrivers. The
role of epidrivers (the genes involved in epigenetic regulation
exhibiting recurrent disruption in cancer through mutational
or nonmutational mechanisms) in carcinogenesis requires par-
ticular attention.29–31 The fact that >50% of human cancers
harbor mutations in enzymes that are involved in chromatin
organization32 argues that epidrivers may represent an early
and central event in tumorigenesis. To conﬁrm this, mechanis-
tic studies of epidrivers altered by speciﬁc carcinogenic agents
should be considered using in vitro human and mouse models
and state-of-the-art approaches (epigenome-wide shRNA or
CRISPR library screens, epigenome editing, and functional
genomics). Characterization of epidriver events is expected to
advance the knowledge of mechanisms of carcinogenesis and
underpin studies of cancer etiology, therapy and prevention.
Analytical considerations
In population-based epigenome-wide studies, the generation,
analysis and interpretation of data are not straightforward.33,34
Several studies demonstrated the robustness of wet lab and bio-
informatics pipelines and capacity to perform epigenome anal-
ysis in high throughput and genome-wide settings; however,
there is a lack of consensus on the pertinent optimal analytical
approaches. While recent studies of epigenome-wide changes
associated with some known risk factors used a GWAS-like
strategy that treats individual CpG sites independently, there is
wide recognition that more advanced approaches (including
CpG regional clusters) may be more informative.34
Epigenetic reversibility, effect size and rate of change. Several
studies highlight the reversibility or lifetime persistence of
some speciﬁc epigenetic changes associated with environmen-
tal exposures (Fig. 1). This seems to depend on multiple fac-
tors, including the type of epigenetic signatures (some CpGs
remain methylated for longer periods than others, given the
same exposure), the level and duration of the exposure, the
tissue type, and the developmental stage (in utero life or
puberty are sensitive periods to exposure and can be prone
to epigenetic alterations with long-term effects). More studies
and cohorts with repeated time points are needed to enhance
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the resolution of the epigenetic snapshots taken at different
developmental stages of life (Fig. 1). Such study designs can
also enable the assessment of the “rate” of change (and not
only the effect size) of DNA methylation in response to
exposure over time. These studies may also need to consider
if the reversal of the change leads to reversal of risk, as
speciﬁc epigenetic events during a critical developmental
period could initiate a program which later in life could be
important, regardless of the continued presence or absence of
that initiator (a “hit and run” effect).
Cell type heterogeneity. This remains a major concern in
epigenetic studies, the deconvolution of which becomes more
intricate in tumor tissues, which exhibit both clonal and
genetic intratumor heterogeneity.35 For example, head and
neck squamous cell carcinomas exhibit extensive heterogene-
ity in etiological, environmental, cellular and molecular fea-
tures, hampering accurate prognosis, treatment planning and
identiﬁcation of causative genes that may serve as molecular
drug targets.36–38 Recent advances in bioinformatics have
helped correct for possible changes in cell subpopulations
using DNA methylome-based prediction algorithms that rely
on reference tissues (initially using peripheral blood39 and
recently cord blood40) and reference-free methods (a recent
but rapidly developing ﬁeld.41,42 Emerging methods for
single-cell epigenomics should also provide exciting tools for
resolving the issues related to the variability of the epigenome
among different cells and cell clones in complex tissues.43,44
Target tissue. Epigenetic changes are abundant and directly
measureable in tumor biopsies, especially when compared
with adjacent tissue. However, aberrant DNA methylation
has also been observed in surrogate tissues such as peripheral
blood of cancer patients. Epigenetic alterations can arise in
early stages of embryonic development, when epigenetic pat-
terns undergo large-scale reprogramming (Fig. 3), and, hence,
may be propagated in most, if not all, tissues, thereby gener-
ating identical constitutional epimutations throughout the
body7 or creating a mosaic pattern of the epigenome in a
given organ.45 In this scenario, the timing of the epigenetic
event and proliferation history of the affected cells will deter-
mine the proportion and distribution of the cells harboring
Figure 3. Constitutional epimutations and epigenetic mosaicism as a mechanism of cancer causality and targets for biomarker discovery.
Although epigenetic patterns are tissue specific, interrogating the epigenome in tissues that are not the target tissue (surrogates) may
be informative of exposure history and cancer risk. Environmental exposure, stochastic event, or even germline epimutation may be
propagated over life course and result in epigenetic mosaicism or germline epimutations across tissues which may constitute an increased
susceptibility to cancer.
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epimutations across different tissues (Fig. 3). These consider-
ations provide the basis for developing epigenetic biomarkers
in blood, which can serve as a surrogate for diagnostics and
risk stratiﬁcation of cancer in other tissues. For example,
methylation of SEPT9 has been shown to be a reliable
and sensitive blood-based biomarkes for colorectal cancer
detection.46
Besides blood and urine samples, additional body ﬂuids
and different types of biospecimens collected through nonin-
vasive or minimally invasive techniques, such as buccal
swabs, breast lavage and cervical smears, may provide attrac-
tive targets for the discovery of biomarkers of exposure or
early detection of cancer.
Early-life exposures
As described earlier, “windows of vulnerability” exist during
in utero development, within which maternal exposure fac-
tors may alter the fetal epigenome, increasing susceptibility to
later-onset diseases, including cancer.47 A recent example
illustrates the complex association between in utero exposure
to tobacco smoke and childhood cancer. A study of neonatal
blood spots showed that DNA methylation at birth was
altered in association with early pregnancy maternal folate
status.48 DNA methylation marks of smoking demonstrated a
difference between cases and controls (J. Wiemels, unpub-
lished data), consistent with the interaction between maternal
smoking in cancer risk in the offspring.49 International col-
laboration on such a rare disease (to assimilate large samples
and replicate ﬁndings in multiple cohorts) may help decipher
this complex exposure-to-phenotype pattern.
Epigenetic clock and cancer risk
One of the best-characterized DNA methylation signatures in
population-based studies is chronological age. Age-associated
epigenetic changes have been identiﬁed and provide the basis
for an “epigenetic clock.”50 Age is the strongest demographic
risk factor for cancer, indicating that molecular changes upon
aging trigger malignant transformation.51 DNA methylation
clock may be affected by different external and endogenous
factors. Those exposures may contribute to methylation
drift52 and “accelerated” aging, emphasizing that the often
ignored rate of change in methylation can be important even
though the magnitude of methylation differences might be
minimal. As DNA methylation landscape is altered as a func-
tion of age (independently of exposures), there is a need to
explore synergistic epigenetic effects between age and envi-
ronmental exposures. For instance, DNA methylation proﬁl-
ing in a large prospective cohort revealed an association
between the epigenetic age acceleration and breast cancer
risk,53 although further studies are needed to establish the
synergy between exposure and age. Importantly, age-
associated epigenetic silencing of HAND2 seems to be an
early event in endometrial carcinogenesis, leading to gradual
inactivation of the progesterone tumor suppressor pathway
and sensitizing endometrial epithelial cells to oncogenic
estrogen.54 Therefore, this may serve as a paradigm for
aging-associated epigenetic changes sensitizing (priming) the
cells for subsequent exposure to oncogenic stimuli. Further
studies are needed to test the presence of synergistic age-
exposure mediating effects on the DNA methylome and can-
cer risk.
Toward incorporating epigenetic data into carcinogen
identification and evaluation
Recent advances in epigenetics represent an exciting opportu-
nity toward the incorporation of epigenetic mechanisms into
carcinogen evaluation and safety assessment (Fig. 2). In spite
of recent data on epigenetic mechanisms as biological media-
tors of certain exposures (such as EDCs discussed above),
evidence for a causal role of epigenetic changes in carcino-
genesis is limited. Although the incorporation of epigenetic
mechanisms into carcinogen evaluation is at an early
stage,21,55 important data have been generated, and valuable
scientiﬁc resources could be applied in the main international
programs of carcinogen evaluation (such as the IARC Mono-
graphs Programs and National Toxicology Programs in the
US). There will be value in designing integrated approaches
aiming to interrogate all layers of the epigenome in response
to carcinogen exposure in populations followed by validation
in population-based studies and functional characterization
in in vitro model systems (Fig. 2). There is an urgent need to
develop epigenetic assays that incorporate scientiﬁcally sound
experimental designs with particular consideration for dose
and route of exposure. Identifying a set of priority carcino-
gens to be studied in detail will be an important start. We
propose that particular attention should be paid to potential
“epigenetic carcinogens” (such are those classiﬁed by IARC
as probably carcinogenic or possibly carcinogenic to humans
[Groups 2 A and 2B] that seem to act through nonmuta-
tional mechanisms), as opposed to established mutagens.
Conclusions
Remarkable progress in the ﬁeld of epigenetics provides a bet-
ter understanding of the etiology of human cancers and sug-
gests a potential causal role for epigenetic disruptions linking
environmental exposure to tumorigenesis. The emergence of
powerful sequencing technologies has enabled the analysis of
the epigenome with high resolution in both genome-wide and
high-throughput settings, thus dramatically accelerating inves-
tigations in cancer biology and molecular epidemiology. Major
international efforts have brought about critical advances,
with the establishment of reference epigenomes for many nor-
mal cell types and cancer-speciﬁc epigenomes for several
tumor types. Recent studies contributed to the identiﬁcation
of epigenetic events deregulated by speciﬁc environmental and
lifestyle stressors, supporting the hypothesis that the epige-
nome may function as an interface between environmental
factors and the genome. Importantly, many studies provided
evidence that environmental exposures can induce speciﬁc
changes in the epigenome. Such epigenetic “ﬁngerprints” will
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prove instrumental in carcinogen evaluation and identiﬁcation
and in the discovery of new biomarkers for risk stratiﬁcation
and novel interventions for prevention.
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